Moreover, the effects of therapeutically modulating GITR by antibodies like DTA-1 or recombinant ligand do not reflect the consequences of GITR interaction with its natural, tumor-expressed ligand in vivo. This evidence concerns the gene TNFRSF18 and neoplasm.